Lumentum (LITE) EVP Vincent Retort sells stock under Rule 10b5-1 plan

Rhea-AI Filing Summary

Lumentum Holdings Inc. executive Vincent Retort, Executive Vice President for the Module Business Unit R&D and Product Development, reported a series of open-market sales of common stock on February 12, 2026. The transactions were coded as sales and executed at prices ranging from about $575.80 to $602.19 per share, across multiple trades.

The filing states these shares were sold under a pre-established Rule 10b5-1 trading plan adopted on November 13, 2025. Following the reported sales, Retort directly held 102,455 shares of Lumentum common stock.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Retort Vincent

(Last) (First) (Middle)

C/O LUMENTUM HOLDINGS INC.

1001 RIDDER PARK DRIVE

(Street)

SAN JOSE CA 95131

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Lumentum Holdings Inc. [ LITE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SEE REMARKS

3. Date of Earliest Transaction (Month/Day/Year)
02/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/12/2026		S(1)		450	D	$576.3523(2)	147,031	D
Common Stock	02/12/2026		S(1)		386	D	$577.283(3)	146,645	D
Common Stock	02/12/2026		S(1)		250	D	$578.594(4)	146,395	D
Common Stock	02/12/2026		S(1)		1,363	D	$579.6578(5)	145,032	D
Common Stock	02/12/2026		S(1)		2,399	D	$580.3438(6)	142,633	D
Common Stock	02/12/2026		S(1)		1,068	D	$581.4928(7)	141,565	D
Common Stock	02/12/2026		S(1)		260	D	$582.5692(8)	141,305	D
Common Stock	02/12/2026		S(1)		170	D	$584.8385(9)	141,135	D
Common Stock	02/12/2026		S(1)		2,170	D	$586.2886(10)	138,965	D
Common Stock	02/12/2026		S(1)		910	D	$587.2794(11)	138,055	D
Common Stock	02/12/2026		S(1)		1,368	D	$588.4333(12)	136,687	D
Common Stock	02/12/2026		S(1)		3,593	D	$589.7011(13)	133,094	D
Common Stock	02/12/2026		S(1)		3,738	D	$590.5582(14)	129,356	D
Common Stock	02/12/2026		S(1)		7,673	D	$591.8233(15)	121,683	D
Common Stock	02/12/2026		S(1)		1,953	D	$592.7779(16)	119,730	D
Common Stock	02/12/2026		S(1)		2,888	D	$593.7391(17)	116,842	D
Common Stock	02/12/2026		S		3,576	D	$594.7973(18)	113,266	D
Common Stock	02/12/2026		S(1)		2,939	D	$595.8707(19)	110,327	D
Common Stock	02/12/2026		S(1)		1,626	D	$597.0391(20)	108,701	D
Common Stock	02/12/2026		S(1)		2,959	D	$598.0859(21)	105,742	D
Common Stock	02/12/2026		S(1)		1,516	D	$599.5127(22)	104,226	D
Common Stock	02/12/2026		S(1)		650	D	$600.1785(23)	103,576	D
Common Stock	02/12/2026		S		1,121	D	$601.8192(24)	102,455	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025.

2. These sales were executed in multiple trades at prices ranging from $575.795 to $576.665. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide full information regarding the number of shares sold at each separate price, within the ranges set forth in footnotes (2) through (24) to this Form 4, upon request, to the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer.

3. These sales were executed in multiple trades at prices ranging from $577.00 to $577.50.

4. These sales were executed in multiple trades at prices ranging from $578.00 to $578.99.

5. These sales were executed in multiple trades at prices ranging from $579.00 to $579.8975.

6. These sales were executed in multiple trades at prices ranging from $580.00 to $580.97.

7. These sales were executed in multiple trades at prices ranging from $581.03 to $582.00.

8. These sales were executed in multiple trades at prices ranging from $582.50 to $582.60.

9. These sales were executed in multiple trades at prices ranging from $584.34 to $585.305.

10. These sales were executed in multiple trades at prices ranging from $585.68 to $586.60.

11. These sales were executed in multiple trades at prices ranging from $587.00 to $587.60.

12. These sales were executed in multiple trades at prices ranging from $588.01 to $588.98.

13. These sales were executed in multiple trades at prices ranging from $589.045 to $589.98.

14. These sales were executed in multiple trades at prices ranging from $590.09 to $591.07.

15. These sales were executed in multiple trades at prices ranging from $591.26 to $592.225.

16. These sales were executed in multiple trades at prices ranging from $592.275 to $593.27.

17. These sales were executed in multiple trades at prices ranging from $593.30 to $594.295.

18. These sales were executed in multiple trades at prices ranging from $594.48 to $595.45.

19. These sales were executed in multiple trades at prices ranging from $595.50 to $596.25.

20. These sales were executed in multiple trades at prices ranging from $596.61 to $597.50.

21. These sales were executed in multiple trades at prices ranging from $597.63 to $598.515.

22. These sales were executed in multiple trades at prices ranging from $598.88 to $599.84.

23. These sales were executed in multiple trades at prices ranging from $599.97 to $600.88.

24. These sales were executed in multiple trades at prices ranging from $601.30 to $602.185.

Remarks:

Officer title: Executive Vice President, Module Business Unit R&D and Product Development

	/s/ Jae Kim as Attorney-in-Fact	02/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Lumentum (LITE) report for Vincent Retort?

Lumentum reported that executive Vincent Retort sold common stock in a series of open-market transactions on February 12, 2026. The trades were disclosed on Form 4 and involved multiple small blocks of shares executed at various prices throughout the trading day.

On what date did the Lumentum (LITE) insider stock sales by Vincent Retort occur?

All reported insider stock sales by Vincent Retort occurred on February 12, 2026. Each transaction in Lumentum common stock shares that day was recorded separately, reflecting distinct trade sizes and execution prices, and then aggregated in the Form 4 filing for regulatory disclosure.

At what prices did Vincent Retort sell Lumentum (LITE) shares?

Vincent Retort’s Lumentum stock sales were executed at prices ranging roughly from $575.80 to $602.19 per share. Each Form 4 line reports a weighted average price, with footnotes describing underlying trade price ranges within those bands for the separate groups of transactions.

How many Lumentum (LITE) shares does Vincent Retort own after the reported sales?

After the reported transactions, Vincent Retort directly owned 102,455 shares of Lumentum common stock. This post-transaction holding is shown in the Form 4’s “Amount of Securities Beneficially Owned Following Reported Transaction(s)” column for the final line item in the non-derivative securities table.

Were the Lumentum (LITE) insider sales by Vincent Retort under a Rule 10b5-1 plan?

Yes. The Form 4 states the shares were sold pursuant to a Rule 10b5-1 trading plan that Vincent Retort adopted on November 13, 2025. Such plans prearrange sales, allowing executives to systematically sell shares according to preset instructions over time.

What role does Vincent Retort hold at Lumentum (LITE)?

The Form 4 identifies Vincent Retort as an officer of Lumentum, with the remarks specifying his title as Executive Vice President, Module Business Unit R&D and Product Development. This means he is a senior executive responsible for research, development, and product efforts in that business area.